A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT ID: NCT06163898
Last Updated: 2025-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
156 participants
INTERVENTIONAL
2024-02-27
2025-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06988488
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843
A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT02963493
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
NCT01335399
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
NCT05981209
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part A
Alnuctamab
Specified dose on specified days
Mezigdomide
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Arm B1
Alnuctamab
Specified dose on specified days
Mezigdomide
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Arm B2
Alnuctamab
Specified dose on specified days
Mezigdomide
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Arm C1
Alnuctamab
Specified dose on specified days
Mezigdomide
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Arm C2
Alnuctamab
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alnuctamab
Specified dose on specified days
Mezigdomide
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Part A: Have previously received ≥ 3 prior lines of anti-myeloma therapy.
* Part B and Part C: Have received 1 to 3 prior lines of anti-myeloma therapy.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0033
Birmingham, Alabama, United States
Local Institution - 0035
New Haven, Connecticut, United States
Local Institution - 0018
New York, New York, United States
Local Institution - 0021
Petah Tikva, Central District, Israel
Local Institution - 0030
Ramat Gan, Central District, Israel
Local Institution - 0020
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-504367-16-00
Identifier Type: OTHER
Identifier Source: secondary_id
U1111-1283-8970
Identifier Type: OTHER
Identifier Source: secondary_id
CA058-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.